Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Children's Oncology Group
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Nebraska
Eli Lilly and Company
Hoffmann-La Roche